Integrated analysis of disulfidoptosis-related genes identifies NRP1 as a novel biomarker promoting proliferation of gastric cancer via glutamine mediated energy metabolism
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies 31 disulfidptosis-related genes (DRGs) as a novel prognostic signature for stomach adenocarcinoma (STAD). This signature predicts patient survival and reveals links to the tumor immune microenvironment, offering new therapeutic targets.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Genomics
Background
- Gastric cancer is a leading cause of cancer incidence and mortality globally.
- Disulfidptosis, a novel cell death pathway, is implicated in cancer initiation and progression.
- Understanding molecular drivers in stomach adenocarcinoma (STAD) is crucial for improved patient outcomes.
Purpose Of The Study
- To develop a prognostic signature based on disulfidptosis-related genes (DRGs) for STAD.
- To investigate the association between the DRG signature and the tumor immune microenvironment (TME).
- To identify potential therapeutic targets and biomarkers for STAD management.
Main Methods
- Gene expression profiling and bioinformatics analyses.
- Machine learning algorithms and Cox regression models for signature development.
- Correlation analysis with TME characteristics and functional validation of key genes.
Main Results
- A 31-DRG prognostic signature for STAD was established, demonstrating significant predictive power for overall survival.
- The DRG signature effectively predicted patient outcomes across multiple datasets, outperforming traditional clinicopathological factors.
- The signature correlated with TME features, suggesting implications for immune modulation in STAD.
- NRP1 was identified as a key DRG, upregulated in STAD and associated with advanced disease and poor prognosis, promoting proliferation via glutamine metabolism.
Conclusions
- The 31-DRG signature serves as a robust prognostic biomarker for STAD.
- DRGs offer potential targets for novel immunotherapeutic strategies in STAD.
- NRP1 plays a critical role in STAD progression and represents a potential therapeutic target.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.